Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 10;19(1):325.
doi: 10.1186/s12887-019-1710-5.

Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s

David A Geier  1   2 , Janet K Kern  3   4 , Mark R Geier  1   2
Affiliations

Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s

David A Geier et al. BMC Pediatr. .

Abstract

Background: Measles (rubeola) is a highly contagious disease with significant morbidity/mortality. Measles-Mumps-Rubella (MMR) is a live-attenuated vaccine used in the United States (US) since the early 1970s to prevent measles infection. This retrospective longitudinal cohort study examined childhood MMR vaccination effectiveness (VE) on preventing diagnosed measles cases.

Methods: The Independent Healthcare Research Database (IHRD) is composed of non-identifiable linked eligibility and claim healthcare records prospectively generated from the Florida Medicaid system. The SAS system was utilized to examine a cohort of 101,736 persons eligible for Florida Medicaid from 1990 to 2009 and continuously eligible with ≥10 outpatient office visits during the 120-month period following birth. There were 32,870 persons (224,492 person-years) in the cohort receiving a single dose of childhood MMR vaccine (vaccinated) and 43,538 persons (434,637 person-years) in an unvaccinated cohort (no exposures to measles-containing vaccine). The frequency of diagnosed measles (ICD-9 code: 055xxx) was examined. Cox proportional hazards models evaluated MMR vaccination and diagnosed measles over time.

Results: MMR vaccinated cohort members were at significantly reduced risk of measles in the unadjusted (VE = 83.6, 95% CI = 67.2-91.8%) and adjusted (VE = 80.7, 95% CI = 61.5-83.9%) models as compared to the unvaccinated cohort. VE = 80% among younger MMR recipients (12-15 months), whereas VE = 90% among older MMR recipients (16-20 months) as compared to the unvaccinated cohort.

Conclusion: Routine childhood MMR vaccination significantly reduced the incidence rate of childhood measles infections, and the VE was greater in the older recipients (16-20 months) than in the younger recipients (12-15 months).

Keywords: Cohort; MMR vaccine; Measles; Pediatric; Rubeola.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A schematic flowchart of the data examined in the present study. Persons in the MMR vaccinated cohort received only 1 dose of MMR vaccine and includes only persons diagnosed with measles post-MMR vaccine administration (43 persons were excluded with measles diagnoses pre-MMR vaccine administration and 3 persons were diagnosed measles within 30 days of vaccine administration, which are most likely measles vaccine-associated adverse events)
Fig. 2
Fig. 2
A Cox proportional hazards survival plot evaluating cases of measles diagnosed over the period of follow-up in the MMR vaccinated cohort1 (1) in comparison to the unvaccinated cohort2 (0). 1 Persons received only 1 dose of MMR vaccine. 2 Persons received no doses of measles-containing vaccine
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome and mumps, 2013: summary recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep. 2013;62:1–34. - PubMed
    1. Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the United States. Pediatrics. 1985;76:524–532. - PubMed
    1. Redd SC, Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: WB Saunders; 1999. pp. 222–266.
    1. Schwarz AJ, Jackson JE, Ehrenkranz NJ, Ventura A, Schiff GM, Walters VW. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child. 1975;129(12):1408–12. - PubMed
    1. MERCK & CO., INC., M-M-R-II, Measles Mumps, and Rubella Virus Vaccine Live. http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf. Revised 5/2017; Accessed 18 July 2018.

Publication types

Substances